INDIVIOR PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 746.00 GBX | +2.68% |
|
-6.05% | -37.05% |
| 09-05 | Transcript : Indivior PLC Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM | |
| 09-04 | Indivior reports "disappointing" results for study with Aelis Farma | AN |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Development, Manufacture and Sale of Buprenorphine-Based Prescription Drugs | 785M | 647M | 791M | 901M | 1.09B | |||||
Total Assets | 1.65B | 1.53B | 1.83B | 1.77B | 1.95B | |||||
Interest Expense | -20M | -17M | -18M | -22M | -30M | |||||
Income Tax Expense | 46M | -25M | -15M | -42M | -1M | |||||
CAPEX | -7M | -4M | -34M | -6M | -8M | |||||
EBT | 180M | -173M | 190M | -95M | 1M | |||||
Gross Profit | 645M | 550M | 664M | 742M | 907M | |||||
D&A | 20M | 21M | 19M | 19M | 18M | |||||
Operating Income | 178M | -156M | 213M | -85M | -4M | |||||
Net Income | 134M | -148M | 205M | -53M | 2M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 589M | 456M | 603M | 731M | 912M | |||||
Total Assets | 68M | 141M | 133M | 65M | 214M | |||||
Rest of World (ROW) | 196M | 182M | 181M | 164M | 176M | |||||
Total Assets | 184M | 6M | 5M | 3M | 3M | |||||
United Kingdom | - | 9M | 7M | 6M | 5M | |||||
Total Assets | - | 122M | 145M | 223M | 206M |
- Stock Market
- Equities
- INDV Stock
- Financials Indivior PLC
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition